Improving prediction of lymph node response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer via dynamic [18F]FDG PET/CT
European Radiology · 07.06.2025 · 35 (12) · 8105-8115
DOI: 10.1007/s00330-025-11729-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Radiology, online erschienen am 07.06.2025. Verfasst von Shaopeng Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzho…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Carcinoma, Non-Small-Cell Lung, Fluorodeoxyglucose F18, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: the National Key R&D Program of China, Natural Science Foundation of Guangdong Province, Chin.
Abstract (Originalsprache)
OBJECTIVES: Accurately predicting the pathological response of lymph nodes to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC) remains a challenge. This study aimed to evaluate the effectiveness of [18F]FDG PET/CT imaging in predicting lymph node response to neoadjuvant chemoimmunotherapy in resectable NSCLC. We investigated the predictive value of dynamic changes in imaging features of both primary tumors and lymph nodes. MATERIALS AND METHODS: A total of 86 patients with stage IIB-IIIB NSCLC were enrolled. [18F]FDG PET/CT scans were conducted at baseline and after neoadjuvant chemoimmunotherapy, but before surgery. SUVmax and size of primary tumors and lymph nodes were measured, and their dynamic changes were analyzed to correlate with nodal response. The predictive accuracy was assessed using the area under the receiver operating characteristic curve. Event-free survival (EFS) was evaluated using Kaplan-Meier analysis. RESULTS: The metabolism composite index, which combines changes in SUVmax of the primary tumor and post-treatment SUVmax of lymph nodes, significantly improved lymph node response prediction, with an AUC of 0.852 (95% CI: 0.772, 0.932), sensitivity of 0.783, and specificity of 0.811. Patients without a pathological complete response (pCR) had shorter median EFS in the non-pCR/PET (N+) group compared to the non-pCR/PET (N-) group (17 months vs 42 months, p < 0.001). CONCLUSION: Integrating dynamic metabolic changes in the primary tumor with post-treatment lymph node metabolic status is highly effective in predicting lymph node response to neoadjuvant chemoimmunotherapy. This method also helps identify patients with less favorable prognoses within the non-pCR group. KEY POINTS: Question How effective is [18F]FDG PET/CT in predicting lymph node response to neoadjuvant chemoimmunotherapy in resectable NSCLC through dynamic changes in metabolic features? Findings The integration of SUVmax changes in the primary tumor with post-treatment SUVmax of lymph nodes achieved a predictive accuracy characterized by an AUC of 0.852. Clinical relevance The use of dynamic metabolic changes from [18F]FDG PET/CT enhances the prediction of lymph node response and helps identify NSCLC patients with poor prognosis, allowing for improved risk stratification and targeted postoperative interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Department of Thoracic Surgery, The Third People's Hospital of Shenzhen, Shenzhen, China.
- Shantou University Medical College, Shantou, China.
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Thoracic Surgery, Shenzhen Nanshan People's Hospital, Shenzhen, China.
- Department of Thoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Förderung
- the National Key R&D Program of China
- Natural Science Foundation of Guangdong Province, Chin
Zitieren
APA
Li, S., Wu, J., Li, Z., Xu, H., Zhuang, W., Tang, Y., Xia, X., He, Z., Lan, Z., Mo, A., Chen, Y., Zhong, W., Chen, R., & Qiao, G. (2025). Improving prediction of lymph node response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer via dynamic [18F]FDG PET/CT. European Radiology, 35(12), 8105-8115. https://doi.org/10.1007/s00330-025-11729-4
Vancouver
Li S, Wu J, Li Z, Xu H, Zhuang W, Tang Y, et al. Improving prediction of lymph node response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer via dynamic [18F]FDG PET/CT. European Radiology. 2025;35(12):8105-8115. doi:10.1007/s00330-025-11729-4
BibTeX
@article{Li2025,
author = {Li, Shaopeng and Wu, Junhan and Li, Zijie and Xu, Haijie and Zhuang, Weitao and Tang, Yong and Xia, Xin and He, Zhe and Lan, Zihua and Mo, Aotian and Chen, Yizhang and Zhong, Weifeng and Chen, Rixin and Qiao, Guibin},
title = {Improving prediction of lymph node response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer via dynamic [18F]FDG PET/CT},
journal = {European Radiology},
year = {2025},
volume = {35},
number = {12},
pages = {8105--8115},
doi = {10.1007/s00330-025-11729-4}
}
EUVIMED